Posted on 20 July 2015
The meta-analysis demonstrated that diarrhoea was about one-and-a-half times more likely, and mucositis (treatment-induced ulceration of the mouth, oesophagus and bowel) was over three times as common in patients who had received the monoclonal antibodies.
Dr Miroddi commented that “clinicians and patients need to know about likely side effects when choosing a treatment”. For clinicians and researchers, knowing the key adverse effects should lead to prevention and risk reduction strategies to optimise outcomes.